MEDTIDE (03880) · Company profile · Eqvero

MEDTIDE

03880HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2021
Revenue	570.09 m CNY	442.23 m CNY	336.77 m CNY	282.14 m CNY
Cost of revenue	179.15 m CNY	163.15 m CNY	127.5 m CNY	95.13 m CNY
Research and development expense	29.05 m CNY	28.75 m CNY	23.14 m CNY	17.67 m CNY
Selling, general and administrative expense	120.16 m CNY	115.9 m CNY	71.84 m CNY	57.88 m CNY
Operating profit after depreciation	211.01 m CNY	104.21 m CNY	84.59 m CNY	83.61 m CNY
Operating profit before depreciation	240.34 m CNY	134.3 m CNY	114.37 m CNY	109.93 m CNY
EBIT	211.01 m CNY	104.21 m CNY	84.59 m CNY	83.61 m CNY
EBITDA	240.34 m CNY	134.3 m CNY	114.37 m CNY	109.93 m CNY
Interest expense	1.24 m CNY	1.14 m CNY	224 k CNY	4.44 m CNY
Profit before tax	250.75 m CNY	78.45 m CNY	61.98 m CNY	89.39 m CNY
Income tax expense	33.37 m CNY	19.28 m CNY	13.07 m CNY	9.11 m CNY
Income before extraordinary items	217.37 m CNY	59.17 m CNY	48.91 m CNY	80.28 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.